NPHLA Intelligence

NPHLA Explains

A complex issue translated into plain professional language. Plain-English explainers on complex pharmacy, compounding, regulatory and clinical questions — built from official sources, reviewed by an editor before publication and updated when the facts change.

Answer first. The question is answered in the opening lines, then explained in depth.
Sourced. Every fact links to the official record it comes from.
Reviewed. Drafts may be prepared with AI assistance; an editor reviews every explainer before it is published.
Not advice. Explainers describe rules and evidence; they are not legal, regulatory or clinical advice.

Explainers on Semaglutide

1 total

02RegulatoryNPHLA ExplainsOct 13, 2026
503A or 503B? How the two federal compounding pathways differ — and why it mattered for GLP-1 medicines
Federal law gives compounders two routes, with different rules on prescriptions, quality standards, oversight and copies of approved drugs. Here is how they compare, using GLP-1 compounding as the worked example.
AI-assisted · Editor reviewed6 sources3 min read

Explainers on Semaglutide

503A or 503B? How the two federal compounding pathways differ — and why it mattered for GLP-1 medicines